Chemkart India Ltd has invested Rs 1.00 Crores in its wholly-owned subsidiary, Easy Raw Materials Private Limited, through a rights issue. The investment was made on June 17, 2026, pursuant to the objects of the Initial Public Offer (IPO) as per the prospectus dated July 10, 2025. The funds are earmarked for the commissioning of a manufacturing unit by the subsidiary.

The company allotted 10,00,000 equity shares of face value Rs 10 each at an issue price of Rs 10 per share. This transaction was disclosed to BSE Limited under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Mr. Basavaraj Dalawai, the CFO, signed the intimation on behalf of the company.

Easy Raw Materials Private Limited, incorporated in 2020, is engaged in the trading of pharma products and nutritional supplements. The subsidiary reported a turnover of NIL and a loss after tax of Rs 59.47 Lakhs as of March 31, 2026. Its net worth stood at Rs 578.60 Lakhs during the same period. The post-allotment paid-up share capital of the subsidiary is Rs 7.51 Crores.

The transaction is classified as a related party transaction since the target entity is a wholly-owned subsidiary. It was conducted at arm’s length, and no governmental or regulatory approvals were required for the acquisition. Chemkart maintained 100% shareholding both before and after the allotment.

Financial Details of Easy Raw Materials Private Limited

Investment Breakdown

Chemkart India Limited reported its audited standalone and consolidated financial results for the financial year ended March 31, 2026. The company posted consolidated revenue from operations of ₹21,482.91 lakh for FY26, an increase of 5.7% compared to ₹20,327.85 lakh in the previous year. Profit after tax on a consolidated basis stood at ₹1,965.5 lakh, a decrease of 19.9% from ₹2,453.3 lakh in FY25. The statutory auditors, M/s Bagaria & Co. LLP, issued an unmodified opinion on the financial results.

Financial Performance

The company delivered a measured performance amid a challenging global operating environment, impacted by supply chain disruptions and pricing corrections. Despite these headwinds, revenue was supported by healthy volume growth of approximately 7.1%. The following table summarises the key financial metrics for FY26 on both a standalone and consolidated basis:

For the half-year ended March 31, 2026, standalone revenue from operations was ₹11,050.78 lakh with a profit after tax of ₹1,010.20 lakh. On a consolidated basis, the half-year revenue was ₹11,160.36 lakh with a profit after tax of ₹950.57 lakh. The consolidated net worth strengthened significantly to ₹12,972.98 lakh as of March 31, 2026, from ₹5,328.22 lakh in the prior year, supported by IPO proceeds and sustained earnings growth.

Balance Sheet and Working Capital

The consolidated total assets stood at ₹15,671.1 lakh as of March 31, 2026, up from ₹8,643.9 lakh in the previous year. The table below presents the key asset and working capital metrics:

Cash and cash equivalents increased significantly to ₹3,864.5 lakh from ₹283.1 lakh, bolstered by IPO proceeds. Current borrowings reduced to ₹495.3 lakh from ₹1,692.6 lakh, reinforcing the company's low-leverage position. Capital Work-in-Progress rose to ₹486.8 lakh, reflecting continued progress in the development of the Easy Raw Materials Private Limited (ERMPL) manufacturing facility at JNPA SEZ, Navi Mumbai.

Strategic Outlook

As on March 31, 2026, the company maintained strong business visibility with advance and open orders exceeding ₹6,526 lakh. The company remains focused on research and development, product innovation, and advanced nutraceutical technologies. The ERMPL manufacturing facility at JNPA SEZ is progressing with civil foundation and plinth-level execution activities underway, marking a key milestone in enhancing manufacturing capabilities and improving export competitiveness.